Source-grounded facts extracted from UroGen Pharma Ltd.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
UroGen Pharma Ltd. reported the first quarter ended March 31, 2026 results: revenue ZUSDURI™ generated revenue of $29.2 million in Q1 2026.
“On May 6, 2026, UroGen Pharma Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2026.”
UroGen Pharma Ltd. incurred term loan of up to $250,000,000, to be advanced in two tranches; Tranche A Loan of $200,000,000 funded; Tranche B Loan of $50,000,000 with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC at 8.25% per annum fixed maturing 5th year anniversary of the Tranche A Closing Date.
“On February 26, 2026, UroGen Pharma Ltd. (the “Company”), and UroGen Pharma, Inc., as the borrower (the “Borrower” and, together with the Company, collectively, the “Credit Parties”), entered into a loan agreement (the “Loan Agreement”) with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender”), and BioPharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent”), pursuant to which the Lenders agreed to make term loans to the Borrower in an aggregate principal amount of up to $250,000,000, to be advanced in two tranches (the “Term Loans”).”
UroGen Pharma Ltd. entered into Loan Agreement with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC valued at up to $250,000,000 (effective 2026-02-26).
“On February 26, 2026, UroGen Pharma Ltd. (the “Company”), and UroGen Pharma, Inc., as the borrower (the “Borrower” and, together with the Company, collectively, the “Credit Parties”), entered into a loan agreement (the “Loan Agreement”) with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender”), and BioPharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent”), pursuant to which the Lenders agreed to make term loans to the Borrower in an aggregate principal amount of up to $250,000,000, to be advanced in two tranches (the “Term Loans”).”
Christopher Degnan was appointed as Chief Financial Officer at UroGen Pharma Ltd..
“the Company appointed Christopher Degnan as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective on the Effective Date.”
Don Kim resigned as Chief Financial Officer at UroGen Pharma Ltd..
“pursuant to which Mr. Kim resigned from his positions as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective October 8, 2024”
Fred E. Cohen resigned as Director at UroGen Pharma Ltd..
“On September 12, 2024, Fred E. Cohen, M.D., D.Phil., notified UroGen Pharma Ltd. (the “Company”) of his resignation as a director of the Company, effective immediately.”
UroGen Pharma Ltd. reported the first quarter ended March 31, 2024 results: revenue $18.8 million, net income net loss of $32.3 million or ($0.97) per basic and diluted share, EPS ($0.97) per basic and diluted share. Guidance reaffirmed.
“• Post-hoc analysis of OLYMPUS study for JELMYTO shows disease-free periods more than 47.8 months in LG-UTUC • JELMYTO ® demonstrated continued growth with net product sales of $18.8 million in Q1, compared with $17.2 million in Q1 2023 representing ~10% YoY growth • IND accepted for UGN-103, next-generation novel mitomycin-based formulation of UGN-102 to treat”
UroGen Pharma Ltd. reported the full year 2023 results: revenue $82.7 million.
“Net JELMYTO product revenue for the full year 2023 was $82.7 million, compared to $64.4 million in 2022.”
UroGen Pharma Ltd. reported the fourth quarter of 2023 results: revenue $23.5 million.
“UroGen reported JELMYTO net product revenues of $23.5 million in the fourth quarter of 2023, compared to $18.1 million for the same period in 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.